Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adagene Inc

ADAG
Current price
2.53 USD -0.16 USD (-5.95%)
Last closed 2.58 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 113 925 056 USD
Yield for 12 month +91.67 %
1Y
3Y
5Y
10Y
15Y
ADAG
21.11.2021 - 28.11.2021

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 215123

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

12 USD

P/E ratio

Dividend Yield

Current Year

+18 111 491 USD

Last Year

+9 292 724 USD

Current Quarter

+833 335 USD

Last Quarter

+407 873 USD

Current Year

+18 111 491 USD

Last Year

+9 292 724 USD

Current Quarter

+407 873 USD

Last Quarter

+407 873 USD

Key Figures ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -22 739 812 USD
Operating Margin TTM -2288.81 %
PE Ratio
Return On Assets TTM -11.06 %
PEG Ratio
Return On Equity TTM -24.66 %
Wall Street Target Price 12 USD
Revenue TTM 18 111 492 USD
Book Value 1.6 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -84.8 %
Dividend Yield
Gross Profit TTM 10 175 258 USD
Earnings per share -0.44 USD
Diluted Eps TTM -0.44 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -104.61 %

Dividend Analytics ADAG

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.608
Price Sales TTM 6.4462
Enterprise Value EBITDA -1.9495
Price Book MRQ 1.6546

Financials ADAG

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADAG

For 52 weeks

1.1 USD 4.38 USD
50 Day MA 2.62 USD
Shares Short Prior Month 15 076
200 Day MA 2.18 USD
Short Ratio 0.26
Shares Short 11 098
Short Percent 0.03 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics